Craft

Anavex

Stock Price

$4.6

2024-04-03

Market Capitalization

$379.4 M

2024-04-03

Anavex Summary

Company Summary

Overview
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system diseases, pain and various types of cancer. The Company’s lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Type
Public
Status
Active
Founded
2006
HQ
New York, NY, US | view all locations
Website
http://www.anavex.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Christopher U. Missling
  • Tom Skarpelos, Director

    • Tasos Zografidis, Vice President Clinical Operations

      • Ulrich Elben

        Ulrich Elben, Vice President of Preclinical Operations

      LocationsView all

      2 locations detected

      • New York, NY HQ

        United States

        51 W 52nd St

      • Reno, NV

        United States

        50 W. Liberty, 50 W Liberty St #880

      Anavex Financials

      Summary Financials

      Net income (Q1, 2024)
      ($8.6M)
      Cash (Q1, 2024)
      $143.8M
      EBIT (Q1, 2024)
      ($11.3M)

      Footer menu